What Happened

Michele Rene Muzyka, 61, an Advanced Practice Registered Nurse (APRN) practicing in Cheshire, Connecticut, unlawfully distributed amphetamines and benzodiazepines to individuals who had no legitimate medical need for them — forgoing required medical examinations and instead charging $200 cash per visit.

The conduct spanned from January 2024 through June 2025. Muzyka prescribed Schedule II controlled substances (amphetamines) and Schedule IV controlled substances (benzodiazepines) without conducting proper medical evaluations. Among those she prescribed to was an undercover federal agent posing as a Medicaid beneficiary, whose controlled substance prescriptions were paid for by the Medicaid program.

On January 21, 2026, Muzyka pleaded guilty to possession with intent to distribute, distribution, and dispensing of controlled substances. Sentencing was scheduled for April 30, 2026.

What Went Wrong

An APRN operated a cash-only prescribing practice for controlled substances over more than a year without regulatory detection. Several systemic failures contributed:

  • No legitimate medical evaluation. Federal law requires that controlled substance prescriptions be issued for a legitimate medical purpose in the course of professional practice. Skipping examinations entirely eliminated the foundational safeguard against prescribing without medical basis.
  • Cash-only payment structure obscured the practice. Charging a flat $200 cash fee per visit, outside of normal insurance billing, reduced the paper trail and oversight that insurance claims and Medicaid audits would otherwise provide.
  • Prescription drug monitoring program (PDMP) oversight gaps. A prescriber issuing controlled substances across a broad patient population without medical records should generate patterns detectable through PDMP analysis — high-volume prescribing, prescribing without corresponding diagnoses, or cash-pay patients receiving Schedule II substances.
  • Medicaid fraud compounded harm. Prescriptions issued to an undercover Medicaid beneficiary were billed to the Medicaid program, meaning public funds paid for illegitimately obtained controlled substances.

How It Could Have Been Prevented

  • Ensure state PDMP systems flag prescribers whose controlled substance prescribing volume is inconsistent with their documented patient panel or specialty, and route those flags to licensing boards for review.
  • Require documentation of clinical examinations and diagnoses in patient records for every controlled substance prescription, with records subject to periodic audit by licensing or regulatory authorities.
  • Implement Medicaid and insurance claim audits that cross-reference controlled substance claims against clinical documentation — cash-only visits are a known red flag for pill-mill operations.
  • Train pharmacy staff to recognize prescribing patterns that suggest dispensing without legitimate medical need: same prescriber, high-volume Schedule II or IV prescriptions, no diagnosis codes, cash-pay patients.
  • Use DEA and state board complaint mechanisms when pharmacists observe prescribing patterns inconsistent with legitimate practice — corresponding responsibility applies.
  • Conduct peer review of APRN and other mid-level prescriber controlled substance patterns at the institutional level, not only at the individual prescriber level.

Related Guidance

  • 15 Red Flags of Drug Diversion — Prescriber and patient behavioral indicators that suggest controlled substances are not being dispensed for legitimate medical purposes.
  • Corresponding Responsibility Guide — Pharmacist obligations when filling prescriptions that may not be issued for a legitimate medical purpose.
  • Investigation Playbook — How to document and escalate concerns about potentially fraudulent prescribing.
  • Analytics Dashboard — Using dispensing data to identify unusual prescriber patterns that warrant further review.
  • Diversion Trends — Current enforcement trends including mid-level prescriber diversion and PDMP enforcement actions.